PDB Short entry for 2QLF HEADER HYDROLASE/HYDROLASE INHIBITOR 12-JUL-07 2QLF TITLE CRYSTAL STRUCTURE OF CASPASE-7 WITH INHIBITOR AC-DNLD-CHO COMPND MOL_ID: 1; COMPND 2 MOLECULE: CASPASE-7; COMPND 3 CHAIN: A, C; COMPND 4 FRAGMENT: P20 SUBUNIT; COMPND 5 SYNONYM: CASP-7, ICE-LIKE APOPTOTIC PROTEASE 3, ICE-LAP3, APOPTOTIC COMPND 6 PROTEASE MCH-3, CMH-1; COMPND 7 EC: 3.4.22.60; COMPND 8 ENGINEERED: YES; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: CASPASE-7; COMPND 11 CHAIN: B, D; COMPND 12 FRAGMENT: P10 SUBUNIT; COMPND 13 SYNONYM: CASP-7, ICE-LIKE APOPTOTIC PROTEASE 3, ICE-LAP3, APOPTOTIC COMPND 14 PROTEASE MCH-3, CMH-1; COMPND 15 EC: 3.4.22.60; COMPND 16 ENGINEERED: YES; COMPND 17 MOL_ID: 3; COMPND 18 MOLECULE: INHIBITOR AC-DNLD-CHO; COMPND 19 CHAIN: E, F; COMPND 20 ENGINEERED: YES; COMPND 21 MOL_ID: 4; COMPND 22 MOLECULE: PEPTIDE QGHGE; COMPND 23 CHAIN: G; COMPND 24 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CASP7, MCH3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET23B; SOURCE 11 MOL_ID: 2; SOURCE 12 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 13 ORGANISM_COMMON: HUMAN; SOURCE 14 ORGANISM_TAXID: 9606; SOURCE 15 GENE: CASP7, MCH3; SOURCE 16 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 17 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 18 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 19 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 20 EXPRESSION_SYSTEM_PLASMID: PET23B; SOURCE 21 MOL_ID: 3; SOURCE 22 SYNTHETIC: YES; SOURCE 23 MOL_ID: 4; SOURCE 24 SYNTHETIC: YES KEYWDS CYSTEINE PROTEASE, APOPTOSIS, THIOL PROTEASE, ZYMOGEN, HYDROLASE- KEYWDS 2 HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.AGNISWAMY,B.FANG,I.WEBER REVDAT 7 15-NOV-23 2QLF 1 REMARK REVDAT 6 30-AUG-23 2QLF 1 LINK REVDAT 5 13-JUL-11 2QLF 1 VERSN REVDAT 4 24-FEB-09 2QLF 1 VERSN REVDAT 3 29-APR-08 2QLF 1 REMARK REVDAT 2 09-OCT-07 2QLF 1 JRNL REVDAT 1 28-AUG-07 2QLF 0 JRNL AUTH J.AGNISWAMY,B.FANG,I.T.WEBER JRNL TITL PLASTICITY OF S2-S4 SPECIFICITY POCKETS OF EXECUTIONER JRNL TITL 2 CASPASE-7 REVEALED BY STRUCTURAL AND KINETIC ANALYSIS. JRNL REF FEBS J. V. 274 4752 2007 JRNL REFN ISSN 1742-464X JRNL PMID 17697120 JRNL DOI 10.1111/J.1742-4658.2007.05994.X REMARK 2 REMARK 2 RESOLUTION. 2.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 76.6 REMARK 3 NUMBER OF REFLECTIONS : 13827 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.196 REMARK 3 FREE R VALUE : 0.229 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 799 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3828 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 59 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : NULL REMARK 3 BOND ANGLES (DEGREES) : NULL REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2QLF COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-AUG-07. REMARK 100 THE DEPOSITION ID IS D_1000043745. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 28-JUN-06 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.7 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.000 REMARK 200 MONOCHROMATOR : SI 220 REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 13827 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.800 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 76.6 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.09200 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 13.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.90 REMARK 200 COMPLETENESS FOR SHELL (%) : 91.0 REMARK 200 DATA REDUNDANCY IN SHELL : 3.20 REMARK 200 R MERGE FOR SHELL (I) : 0.43000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.550 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 1F1J REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 62.09 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.24 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 14.5% PEG 3350, 0.3M DIAMMONIUM REMARK 280 HYDROGEN CITRATE, 10MM DTT, PH 6.7, VAPOR DIFFUSION, HANGING REMARK 280 DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 32 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+1/3 REMARK 290 6555 -X,-X+Y,-Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 123.88333 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 61.94167 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 61.94167 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 123.88333 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: HEPTAMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D, E, F, G REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 THE INHIBITOR IS COVALENTLY CONNECTED TO CYS OF THE ENZYME TO FORM REMARK 400 A HEMITHIOKETAL REMARK 400 REMARK 400 THE N-ACETYL-L-ALPHA-ASPARTYL-L-ASPARAGINYL-N-[(1R)-2-CARBOXY-1- REMARK 400 FORMYLETHYL]-L-LEUCINAMIDE IS PEPTIDE-LIKE, A MEMBER OF INHIBITOR REMARK 400 CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: N-ACETYL-L-ALPHA-ASPARTYL-L-ASPARAGINYL-N-[(1R)-2-CARBOXY-1- REMARK 400 FORMYLETHYL]-L-LEUCINAMIDE REMARK 400 CHAIN: E, F REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 24 REMARK 465 LYS A 25 REMARK 465 PRO A 26 REMARK 465 ASP A 27 REMARK 465 ARG A 28 REMARK 465 SER A 29 REMARK 465 SER A 30 REMARK 465 PHE A 31 REMARK 465 VAL A 32 REMARK 465 PRO A 33 REMARK 465 SER A 34 REMARK 465 LEU A 35 REMARK 465 PHE A 36 REMARK 465 SER A 37 REMARK 465 LYS A 38 REMARK 465 LYS A 39 REMARK 465 LYS A 40 REMARK 465 LYS A 41 REMARK 465 ASN A 42 REMARK 465 VAL A 43 REMARK 465 THR A 44 REMARK 465 MET A 45 REMARK 465 ARG A 46 REMARK 465 SER A 47 REMARK 465 ILE A 48 REMARK 465 LYS A 49 REMARK 465 THR A 50 REMARK 465 THR A 51 REMARK 465 ARG A 52 REMARK 465 ASP A 53 REMARK 465 ARG A 54 REMARK 465 VAL A 55 REMARK 465 PRO A 56 REMARK 465 THR A 57 REMARK 465 ALA B 207 REMARK 465 ASN B 208 REMARK 465 PRO B 209 REMARK 465 ARG B 210 REMARK 465 TYR B 211 REMARK 465 ALA C 324 REMARK 465 LYS C 325 REMARK 465 PRO C 326 REMARK 465 ASP C 327 REMARK 465 ARG C 328 REMARK 465 SER C 329 REMARK 465 SER C 330 REMARK 465 PHE C 331 REMARK 465 VAL C 332 REMARK 465 PRO C 333 REMARK 465 SER C 334 REMARK 465 LEU C 335 REMARK 465 PHE C 336 REMARK 465 SER C 337 REMARK 465 LYS C 338 REMARK 465 LYS C 339 REMARK 465 LYS C 340 REMARK 465 LYS C 341 REMARK 465 ASN C 342 REMARK 465 VAL C 343 REMARK 465 THR C 344 REMARK 465 MET C 345 REMARK 465 ARG C 346 REMARK 465 SER C 347 REMARK 465 ILE C 348 REMARK 465 LYS C 349 REMARK 465 THR C 350 REMARK 465 THR C 351 REMARK 465 ARG C 352 REMARK 465 ASP C 353 REMARK 465 ARG C 354 REMARK 465 VAL C 355 REMARK 465 PRO C 356 REMARK 465 ALA D 507 REMARK 465 ASN D 508 REMARK 465 PRO D 509 REMARK 465 ARG D 510 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 GLY A 152 N - CA - C ANGL. DEV. = -16.0 DEGREES REMARK 500 GLY C 452 N - CA - C ANGL. DEV. = -15.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 143 -172.30 -177.16 REMARK 500 CYS A 171 85.46 -174.78 REMARK 500 THR A 173 -9.64 -59.31 REMARK 500 HIS B 272 43.18 -95.25 REMARK 500 SER B 277 140.32 -175.69 REMARK 500 SER B 302 -177.18 -173.90 REMARK 500 ASP C 413 60.62 35.40 REMARK 500 SER C 443 -164.87 -171.99 REMARK 500 CYS C 471 59.01 -141.10 REMARK 500 ASP D 555 -1.28 -144.72 REMARK 500 PRO D 589 -178.06 -66.03 REMARK 500 SER D 602 -167.49 -129.84 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN E OF INHIBITOR AC-DNLD REMARK 800 -CHO REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN F OF INHIBITOR AC-DNLD REMARK 800 -CHO REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN G OF PEPTIDE QGHGE REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2QL5 RELATED DB: PDB REMARK 900 RELATED ID: 2QL7 RELATED DB: PDB REMARK 900 RELATED ID: 2QL9 RELATED DB: PDB REMARK 900 RELATED ID: 2QLB RELATED DB: PDB REMARK 900 RELATED ID: 2QLJ RELATED DB: PDB DBREF 2QLF A 24 196 UNP P55210 CASP7_HUMAN 24 196 DBREF 2QLF B 207 303 UNP P55210 CASP7_HUMAN 207 303 DBREF 2QLF C 324 496 UNP P55210 CASP7_HUMAN 24 196 DBREF 2QLF D 507 603 UNP P55210 CASP7_HUMAN 207 303 DBREF 2QLF E 701 705 PDB 2QLF 2QLF 701 705 DBREF 2QLF F 801 805 PDB 2QLF 2QLF 801 805 DBREF 2QLF G 810 814 PDB 2QLF 2QLF 810 814 SEQRES 1 A 173 ALA LYS PRO ASP ARG SER SER PHE VAL PRO SER LEU PHE SEQRES 2 A 173 SER LYS LYS LYS LYS ASN VAL THR MET ARG SER ILE LYS SEQRES 3 A 173 THR THR ARG ASP ARG VAL PRO THR TYR GLN TYR ASN MET SEQRES 4 A 173 ASN PHE GLU LYS LEU GLY LYS CYS ILE ILE ILE ASN ASN SEQRES 5 A 173 LYS ASN PHE ASP LYS VAL THR GLY MET GLY VAL ARG ASN SEQRES 6 A 173 GLY THR ASP LYS ASP ALA GLU ALA LEU PHE LYS CYS PHE SEQRES 7 A 173 ARG SER LEU GLY PHE ASP VAL ILE VAL TYR ASN ASP CYS SEQRES 8 A 173 SER CYS ALA LYS MET GLN ASP LEU LEU LYS LYS ALA SER SEQRES 9 A 173 GLU GLU ASP HIS THR ASN ALA ALA CYS PHE ALA CYS ILE SEQRES 10 A 173 LEU LEU SER HIS GLY GLU GLU ASN VAL ILE TYR GLY LYS SEQRES 11 A 173 ASP GLY VAL THR PRO ILE LYS ASP LEU THR ALA HIS PHE SEQRES 12 A 173 ARG GLY ASP ARG CYS LYS THR LEU LEU GLU LYS PRO LYS SEQRES 13 A 173 LEU PHE PHE ILE GLN ALA CYS ARG GLY THR GLU LEU ASP SEQRES 14 A 173 ASP GLY ILE GLN SEQRES 1 B 97 ALA ASN PRO ARG TYR LYS ILE PRO VAL GLU ALA ASP PHE SEQRES 2 B 97 LEU PHE ALA TYR SER THR VAL PRO GLY TYR TYR SER TRP SEQRES 3 B 97 ARG SER PRO GLY ARG GLY SER TRP PHE VAL GLN ALA LEU SEQRES 4 B 97 CYS SER ILE LEU GLU GLU HIS GLY LYS ASP LEU GLU ILE SEQRES 5 B 97 MET GLN ILE LEU THR ARG VAL ASN ASP ARG VAL ALA ARG SEQRES 6 B 97 HIS PHE GLU SER GLN SER ASP ASP PRO HIS PHE HIS GLU SEQRES 7 B 97 LYS LYS GLN ILE PRO CYS VAL VAL SER MET LEU THR LYS SEQRES 8 B 97 GLU LEU TYR PHE SER GLN SEQRES 1 C 173 ALA LYS PRO ASP ARG SER SER PHE VAL PRO SER LEU PHE SEQRES 2 C 173 SER LYS LYS LYS LYS ASN VAL THR MET ARG SER ILE LYS SEQRES 3 C 173 THR THR ARG ASP ARG VAL PRO THR TYR GLN TYR ASN MET SEQRES 4 C 173 ASN PHE GLU LYS LEU GLY LYS CYS ILE ILE ILE ASN ASN SEQRES 5 C 173 LYS ASN PHE ASP LYS VAL THR GLY MET GLY VAL ARG ASN SEQRES 6 C 173 GLY THR ASP LYS ASP ALA GLU ALA LEU PHE LYS CYS PHE SEQRES 7 C 173 ARG SER LEU GLY PHE ASP VAL ILE VAL TYR ASN ASP CYS SEQRES 8 C 173 SER CYS ALA LYS MET GLN ASP LEU LEU LYS LYS ALA SER SEQRES 9 C 173 GLU GLU ASP HIS THR ASN ALA ALA CYS PHE ALA CYS ILE SEQRES 10 C 173 LEU LEU SER HIS GLY GLU GLU ASN VAL ILE TYR GLY LYS SEQRES 11 C 173 ASP GLY VAL THR PRO ILE LYS ASP LEU THR ALA HIS PHE SEQRES 12 C 173 ARG GLY ASP ARG CYS LYS THR LEU LEU GLU LYS PRO LYS SEQRES 13 C 173 LEU PHE PHE ILE GLN ALA CYS ARG GLY THR GLU LEU ASP SEQRES 14 C 173 ASP GLY ILE GLN SEQRES 1 D 97 ALA ASN PRO ARG TYR LYS ILE PRO VAL GLU ALA ASP PHE SEQRES 2 D 97 LEU PHE ALA TYR SER THR VAL PRO GLY TYR TYR SER TRP SEQRES 3 D 97 ARG SER PRO GLY ARG GLY SER TRP PHE VAL GLN ALA LEU SEQRES 4 D 97 CYS SER ILE LEU GLU GLU HIS GLY LYS ASP LEU GLU ILE SEQRES 5 D 97 MET GLN ILE LEU THR ARG VAL ASN ASP ARG VAL ALA ARG SEQRES 6 D 97 HIS PHE GLU SER GLN SER ASP ASP PRO HIS PHE HIS GLU SEQRES 7 D 97 LYS LYS GLN ILE PRO CYS VAL VAL SER MET LEU THR LYS SEQRES 8 D 97 GLU LEU TYR PHE SER GLN SEQRES 1 E 5 ACE ASP ASN LEU ASJ SEQRES 1 F 5 ACE ASP ASN LEU ASJ SEQRES 1 G 5 GLN GLY HIS GLY GLU HET ACE E 701 3 HET ASJ E 705 8 HET ACE F 801 3 HET ASJ F 805 8 HETNAM ACE ACETYL GROUP HETNAM ASJ (3S)-3-AMINO-4-HYDROXYBUTANOIC ACID FORMUL 5 ACE 2(C2 H4 O) FORMUL 5 ASJ 2(C4 H9 N O3) FORMUL 8 HOH *59(H2 O) HELIX 1 1 GLY A 89 GLY A 105 1 17 HELIX 2 2 SER A 115 GLU A 128 1 14 HELIX 3 3 ILE A 159 HIS A 165 1 7 HELIX 4 4 PHE A 166 LEU A 175 5 10 HELIX 5 5 TRP B 240 GLY B 253 1 14 HELIX 6 6 GLU B 257 HIS B 272 1 16 HELIX 7 7 ASP B 279 HIS B 283 5 5 HELIX 8 8 ASP C 379 GLY C 383 5 5 HELIX 9 9 GLY C 389 GLY C 405 1 17 HELIX 10 10 SER C 415 GLU C 429 1 15 HELIX 11 11 ILE C 459 HIS C 465 1 7 HELIX 12 12 CYS C 471 LEU C 475 5 5 HELIX 13 13 TRP D 540 GLY D 553 1 14 HELIX 14 14 GLU D 557 PHE D 573 1 17 HELIX 15 15 ASP D 579 HIS D 583 5 5 SHEET 1 A12 PHE A 106 ASN A 112 0 SHEET 2 A12 LYS A 66 ASN A 74 1 N ASN A 74 O TYR A 111 SHEET 3 A12 ALA A 134 LEU A 142 1 O ILE A 140 N ILE A 73 SHEET 4 A12 LYS A 179 GLN A 184 1 O LEU A 180 N PHE A 137 SHEET 5 A12 PHE B 219 TYR B 223 1 O ALA B 222 N PHE A 181 SHEET 6 A12 CYS B 290 SER B 293 -1 O VAL B 292 N PHE B 221 SHEET 7 A12 CYS D 590 SER D 593 -1 O SER D 593 N VAL B 291 SHEET 8 A12 PHE D 519 TYR D 523 -1 N PHE D 521 O VAL D 592 SHEET 9 A12 LYS C 479 GLN C 484 1 N ILE C 483 O ALA D 522 SHEET 10 A12 PHE C 437 LEU C 442 1 N PHE C 437 O LEU C 480 SHEET 11 A12 GLY C 368 ASN C 374 1 N ILE C 371 O ILE C 440 SHEET 12 A12 PHE C 406 ASN C 412 1 O ILE C 409 N ILE C 372 SHEET 1 B 3 GLY A 145 GLU A 146 0 SHEET 2 B 3 VAL A 149 GLY A 152 -1 O VAL A 149 N GLU A 146 SHEET 3 B 3 GLY A 155 PRO A 158 -1 O GLY A 155 N GLY A 152 SHEET 1 C 2 GLY A 188 GLU A 190 0 SHEET 2 C 2 GLY B 228 TYR B 229 1 O GLY B 228 N GLU A 190 SHEET 1 D 3 GLY B 238 SER B 239 0 SHEET 2 D 3 TRP B 232 SER B 234 -1 N SER B 234 O GLY B 238 SHEET 3 D 3 ASN E 703 LEU E 704 -1 O ASN E 703 N ARG B 233 SHEET 1 E 3 GLY C 445 GLU C 446 0 SHEET 2 E 3 VAL C 449 TYR C 451 -1 O VAL C 449 N GLU C 446 SHEET 3 E 3 VAL C 456 PRO C 458 -1 O THR C 457 N ILE C 450 SHEET 1 F 2 GLY C 488 GLU C 490 0 SHEET 2 F 2 GLY D 528 TYR D 529 1 O GLY D 528 N GLU C 490 SHEET 1 G 3 GLY D 538 SER D 539 0 SHEET 2 G 3 TRP D 532 SER D 534 -1 N SER D 534 O GLY D 538 SHEET 3 G 3 ASN F 803 LEU F 804 -1 O ASN F 803 N ARG D 533 LINK SG CYS A 186 C ASJ E 705 1555 1555 1.76 LINK SG CYS C 486 C ASJ F 805 1555 1555 1.74 LINK C ACE E 701 N ASP E 702 1555 1555 1.39 LINK C LEU E 704 N ASJ E 705 1555 1555 1.34 LINK C ACE F 801 N ASP F 802 1555 1555 1.38 LINK C LEU F 804 N ASJ F 805 1555 1555 1.34 SITE 1 AC1 16 ARG A 87 HIS A 144 GLY A 145 GLN A 184 SITE 2 AC1 16 CYS A 186 HOH B 38 TYR B 230 SER B 231 SITE 3 AC1 16 TRP B 232 ARG B 233 SER B 234 PRO B 235 SITE 4 AC1 16 SER B 275 GLN B 276 PHE B 282 HOH E 53 SITE 1 AC2 13 ARG C 387 HIS C 444 GLY C 445 GLN C 484 SITE 2 AC2 13 CYS C 486 HOH D 8 TYR D 530 SER D 531 SITE 3 AC2 13 TRP D 532 ARG D 533 PRO D 535 SER D 575 SITE 4 AC2 13 GLN D 576 SITE 1 AC3 8 GLN A 59 GLN B 260 TYR B 300 GLN B 303 SITE 2 AC3 8 GLN C 359 GLN D 560 TYR D 600 SER D 602 CRYST1 87.464 87.464 185.825 90.00 90.00 120.00 P 32 2 1 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011433 0.006601 0.000000 0.00000 SCALE2 0.000000 0.013202 0.000000 0.00000 SCALE3 0.000000 0.000000 0.005381 0.00000